• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Ramucirumab fails in HER2-negative advanced breast cancer

byMonica ParksandDavid Wang
September 5, 2014
in Chronic Disease, Obstetrics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The addition of ramucirumab, a VEGF-2 receptor blocker, to docetaxel did not significantly increase progression free or overall survival in HER-2 negative advanced breast cancer.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Anti-angiogenic agents have emerged as a new line of chemotherapy and have demonstrated clinical benefit in colorectal, cervical, and epithelial ovarian cancers. Vascular Endothelial Growth Factor (VEGF) receptor-2 has been previously associated with breast cancer metastasis and poor clinical outcomes. Ramucirumab, a monoclonal antibody that blocks VEGF-2 receptors, has been proposed as a potential agent in the treatment of advanced breast cancer. The purpose of this phase III clinical trial was to evaluate progression-free or overall survival of patients on ramucirumab plus docetaxel treatment compared to docetaxel plus placebo. The trial enrolled 1,144 patients with a median follow-up of 18.6 months. At the conclusion of the trial, the authors found no significant differences in progression-free or overall survival with the addition of ramucirumab compared to placebo. Additionally, there was significant toxicity related to the ramucirumab-arm including stomatitis, hypertension, and febrile neutropenia. The strength of this trial is its randomized study design and the large sample size designed to demonstrate progression free survival effects. Based on these results, the authors suggest that anti-angiogenic agents may play only a limited role in the treatment of advanced breast cancer until further understanding of the pathophysiology of vasculogenesis in breast cancer is obtained.

Click to read the study in JCO

Relevant Reading: New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers

In-Depth [randomized controlled trial]: This phase III clinical trial was a randomized, double-blinded, placebo-controlled study that included 1144 patients with HER2 negative, unresectable, locally recurrent or metastatic breast cancer. Patients were recruited from multiple centers, and then assigned to docetaxel plus ramucirumab (n=752) or docetaxel plus placebo (n=382). Primary outcomes measured included median progression free survival (PFS) and overall survival (OS). After a median follow-up of 18.6 months, the median PFS in patients treated with ramucirumab was 9.5 months compared with 8.2 months in patients on placebo (HR 0.88; P = 0.077). Median OS was 27.3 months in patients on ramucirumab compared to placebo (HR 1.01; P = 0.915). Time to progression (TTP) was 9.7 months versus 8.2 months (P = 0.033) for the ramucirumab and placebo arms, respectively. There was a significantly increased frequency of adverse events in the ramucirumab group including stomatitis, epistaxis, hypertension, and febrile neutropenia.

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

RELATED REPORTS

Screening with digital breast tomosynthesis vs mammography associated with significantly lower risk of advanced breast cancer among women with extremely dense breasts at high risk of breast cancer

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

Several factors influence health programs conducted in the African American Church

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: Breast CancerHer2Ramucirumab
Previous Post

Dry eye disease linked to immune diseases and chronic pain

Next Post

Smoking exposure may decrease risk of developing inner eye growths (pterygium)

RelatedReports

2 Minute Medicine Rewind March 4, 2019
Chronic Disease

Screening with digital breast tomosynthesis vs mammography associated with significantly lower risk of advanced breast cancer among women with extremely dense breasts at high risk of breast cancer

June 16, 2022
#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

May 18, 2022
Wellness

Several factors influence health programs conducted in the African American Church

May 18, 2022
#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in  premenopausal women with ER+ breast cancer and ovarian suppression
StudyGraphics

#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in premenopausal women with ER+ breast cancer and ovarian suppression

May 3, 2022
Next Post
Smoking exposure may decrease risk of developing inner eye growths (pterygium)

Smoking exposure may decrease risk of developing inner eye growths (pterygium)

Proton radiotherapy may be effective for refractory pituitary adenomas

Proton radiotherapy may be effective for refractory pituitary adenomas

Levodopa for Parkinson’s disease more effective than newer generation therapies

Deep brain stimulation linked to declining brain function in Parkinson’s patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma
  • Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency
  • Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.